Abstract
The study focuses on enhancing microneedle technology for efficient drug and vaccine delivery through the skin's outer layer. Traditional microneedle manufacturing faces challenges such as complex processes and potential denaturation of active ingredients. The new approach introduces "powder-attached microneedles," involving a silicone adhesive layer for attaching formulated drug or vaccine powders. This method overcomes solubility issues and minimizes the risk of ingredient separation during manufacturing. The research uses ovalbumin and teriparatide as model substances. Results demonstrate successful delivery of dried powder, inducing immune responses comparable to intramuscular administration. Powder-attached microneedles offer advantages like convenience, storage stability, and cost reduction. For teriparatide, powder-attached microneedles show pharmacokinetic properties similar to intradermal administration of liquid formulations, providing rapid dissolution and efficient drug delivery. This innovative approach holds promise for thermally sensitive vaccines and structurally weak formulations.
